Drugs Made In America Acquisition Corp. - Ordinary Shares
Drugs Made In America Acquisition Corp. - Ordinary Shares
Share · KYG2847J1040 · DMAA (XNAS)
Overview Financial Indicators
10,27 USD
NASDAQ (XNAS) · Current prices and charts at MoneyPeak
01.08.2025 18:21

Current Prices from Drugs Made In America Acquisition Corp. - Ordinary Shares

ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
DMAA
USD
01.08.2025 18:21
10,27 USD
0,00 USD

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
0,00 % 0,00 % 0,77 % 1,48 % 1,48 % 1,48 % 1,48 %

Company Profile for Drugs Made In America Acquisition Corp. - Ordinary Shares Share

Drugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.

Company Data

Name Drugs Made In America Acquisition Corp. - Ordinary Shares
Company Drugs Made In America Acquisition Corp. Ordinary Shares
Symbol DMAA
Website https://dmaacorp.com
Primary Exchange XNAS NASDAQ
ISIN KYG2847J1040
Asset Class Share
Sector Financial Services
Industry Shell Companies
CEO Ms. Lynn Stockwell
Market Capitalization 240 Mio
Country United States of America
Currency USD
Employees 0,0 T
Address 1 East Broward Blvd Suite 700, 33301 Fort Lauderdale

Ticker Symbols

Name Symbol
NASDAQ DMAA

More Shares

Investors who hold Drugs Made In America Acquisition Corp. - Ordinary Shares also have the following shares in their portfolio:
LEVERAGE SHA ETP 2072
LEVERAGE SHA ETP 2072 ETC
QIFU TECHN. CL.A  -,00001
QIFU TECHN. CL.A -,00001 Share
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025